 |
Indication & Dosage |
| |
| |
| Intramuscular |
| CONTROL OF ACUTE PSYCHOTIC CONDITIONS |
| Adult:
1-2 mg by deep IM, repeated if necessary every 4-6 hr. |
| Max Dosage: 6 mg daily. |
| |
| Oral |
| SHORT-TERM MANAGEMENT OF ANXIETY DISORDERS |
| Child:
3-5 yr: max 1 mg daily in divided doses; 6-12 yr: max 4 mg daily in divided doses.
Elderly: Initiate at lower dose and increase gradually. |
| Max Dosage: 4 mg daily in divided doses. |
| |
| Intramuscular |
| CONTROL OF ACUTE PSYCHOTIC CONDITIONS |
| Child:
1 mg by deep IM once or twice daily.
Elderly: Initiate at lower dose and increase gradually. |
| |
| Oral |
| SHORT-TERM MANAGEMENT OF ANXIETY DISORDERS |
| Adult:
1-2 mg bid. Max: 6mg daily. Max duration: 12 wk. |
| Max Dosage: 12 wk. |
| |
| Oral |
| MANAGEMENT OF NAUSEA AND VOMITING |
| Child:
3-5 yrs: max 1 mg daily in divided doses; 6-12 yr |
| Max Dosage: 4 mg daily. |
| |
| Oral |
| MANAGEMENT OF NAUSEA AND VOMITING |
| Adult:
1-2 mg bid. Max 6 mg daily |
| |
| Oral |
| TREATMENT OF SCHIZOPHRENIA/PSYCHOSES |
| Child:
Max: 5 mg daily in divided doses adjusted according to age, body weight and response.
Elderly: Initiate at lower dose and increase gradually. |
| Max Dosage: Max: 5 mg daily in divided doses adjusted according |
| |
| Oral |
| TREATMENT OF SCHIZOPHRENIA/PSYCHOSES |
| Adult:
2-5 mg bid gradually increased to 15-20 mg daily, or 40 mg daily in severe or resistant psychoses. Elderly: Initiate at lower dose and increase gradually. |
| |
| Intramuscular |
| CONTROL OF ACUTE PSYCHOTIC CONDITIONS |
| Child:
1 mg by deep IM once or twice daily.
Elderly: Initiate at lower dose and increase gradually. |
|
| |
|
| Administration |
Should be taken with food. |
| |
|
| Precautions |
Cardiovascular disease, epilepsy, angle-closure glaucoma, exposure to extreme temperatures, elderly, parkinson's disease, myasthenia gravis, benign prostatic hyperplasia, DM, renal amd hepatic impairment. Discontinue trifluoperazine at least 48 hr before myelography and do not resume for at least 24 hr after procedure. Do not use trifluoperazine in control of nausea and vomiting occurring either prior to myelography or postprocedure with metrizamide. Pregnancy. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Drowsiness, dry mouth, blurred vision, dizziness, sedation, antimuscarinic affects, postural hypotension, akathisia, muscle weakness, anorexia, insomnia, rash, amenorrhoea, fatigue, increased prolactin levels, extrapyramidal side effects. |
| |
|
| Adverse Drug Reactions |
Neuroleptic malignant syndrome, blood dyscrasias. |
| |
|
| Interactions |
Increased CNS depression with CNS depressants such as opiates or other analgesics, barbiturates or other sedatives, general anaesthetics, or alcohol. Increased risk of side effects with drugs with antimuscarinic properties e.g. TCA, antiparkinsonian drugs. Antagonised effects of dopaminergic drugs such as levodopa. Increased risk of hypotension with antihypertensives, trazodone. Reverses antihypertensive effect of guanethidine. Increased risk of severe extrapyramidal side-effects or severe neurotoxicity with lithium. Possible decrease in absorption with antacids. |
| |
|
|
|
